Innocan Pharma Corporation (TSE:INNO) has released an update.
Innocan Pharma Corporation announced a substantial increase in its 2023 revenues, reaching $13.7 million, a 534% jump from the previous year, largely attributed to the performance of its subsidiary, BI Sky Global Ltd. The company also reported a significant reduction in operating loss and a successful $1.5 million capital raise in March 2024. CEO Iris Bincovich expressed satisfaction with the year’s results and the company’s ongoing efforts toward FDA approval for its innovative CBD delivery platform.
For further insights into TSE:INNO stock, check out TipRanks’ Stock Analysis page.
